ST-246 (tecovirimat monohydrate) suspension formulations
US11433051B2 · kind B2 · utility
1Cited by
4References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 2017 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Nov 27, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.